Acrux Ltd has released a press release.
Appendix 4E and 2018 Financial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Acrux
- Acrux Submits First-To-File Generic of Jublia
- Appendix 4D and Half-Year Report to 31 December 2017
- Axiron Net Sales Quarter to December 2017
- Axiron Patents Appeal Decision
- Axiron Net Sales Quarter to September 2017
Later from Acrux
- Acrux confirms patent challenge for generic of efinaconazole
- Acrux has second generic dossier accepted for review by FDA
- Acrux Receives $2.057m R&D Tax Incentive Rebate
- Appendix 4D and Half-Year Financial Report to 31 Dec 2018
- Jublia Patent Litigation Settlement
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux